Publication: COVID-19 vaccination in patients receiving allergen immunotherapy (AIT) or biologicals-EAACI recommendations.
No Thumbnail Available
Identifiers
Date
2022-08-06
Authors
Jutel, Marek
Torres, Maria J
Palomares, Oscar
Akdis, Cezmi A
Eiwegger, Thomas
Untersmayr, Eva
Barber, Domingo
Zemelka-Wiacek, Magdalena
Kosowska, Anna
Palmer, Elizabeth
Advisors
Journal Title
Journal ISSN
Volume Title
Publisher
John Wiley & Sons
Abstract
Immune modulation is a key therapeutic approach for allergic diseases, asthma and autoimmunity. It can be achieved in an antigen-specific manner via allergen immunotherapy (AIT) or in an endotype-driven approach using biologicals that target the major pathways of the type 2 (T2) immune response: immunoglobulin (Ig)E, interleukin (IL)-5 and IL-4/IL-13 or non-type 2 response: anti-cytokine antibodies and B-cell depletion via anti-CD20. Coronavirus disease 2019 (COVID-19) vaccination provides an excellent opportunity to tackle the global pandemics and is currently being applied in an accelerated rhythm worldwide. The vaccine exerts its effects through immune modulation, induces and amplifies the response against the severe acute respiratory syndrome coronavirus (SARS-CoV-2). Thus, as there may be a discernible interference between these treatment modalities, recommendations on how they should be applied in sequence are expected. The European Academy of Allergy and Clinical Immunology (EAACI) assembled an expert panel under its Research and Outreach Committee (ROC). This expert panel evaluated the evidence and have formulated recommendations on the administration of COVID-19 vaccine in patients with allergic diseases and asthma receiving AIT or biologicals. The panel also formulated recommendations for COVID-19 vaccine in association with biologicals targeting the type 1 or type 3 immune response. In formulating recommendations, the panel evaluated the mechanisms of COVID-19 infection, of COVID-19 vaccine, of AIT and of biologicals and considered the data published for other anti-infectious vaccines administered concurrently with AIT or biologicals.
Description
MeSH Terms
Allergens
Asthma
Biological Products
COVID-19
COVID-19 Vaccines
Desensitization, Immunologic
Humans
Hypersensitivity
Immunoglobulin E
SARS-CoV-2
Vaccination
Asthma
Biological Products
COVID-19
COVID-19 Vaccines
Desensitization, Immunologic
Humans
Hypersensitivity
Immunoglobulin E
SARS-CoV-2
Vaccination
DeCS Terms
Vacunas contra la COVID-19
Antígenos
Anticuerpos
Hipersensibilidad
Desensibilización Inmunológica
Vacunación
Autoinmunidad
Antígenos
Anticuerpos
Hipersensibilidad
Desensibilización Inmunológica
Vacunación
Autoinmunidad
CIE Terms
Keywords
Covid-19, Allergen, Allergy, Biologicals, Immunotherapy, mRNA vaccines
Citation
Jutel M, Torres MJ, Palomares O, Akdis CA, Eiwegger T, Untersmayr E, et al. COVID-19 vaccination in patients receiving allergen immunotherapy (AIT) or biologicals-EAACI recommendations. Allergy. 2022 Aug;77(8):2313-2336